BMO Capital analyst Evan David Seigerman raised the price target on Abbvie (NYSE: ABBV) to $214.00 (from $180.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE